Victory Capital Management
TYRA icon

Victory Capital Management’s Tyra Biosciences TYRA Stock Holding History

Victory Capital Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$583K Sell
15,230
-3,560
-19% -$115K ﹤0.01% 1996
2025
Q4 		$494K Hold
18,790
– – ﹤0.01% 2021
2025
Q3 		$263K Sell
18,790
-25,400
-57% -$290K ﹤0.01% 2169
2025
Q2 		$423K Sell
44,190
-11,960
-21% -$114K ﹤0.01% 2087
2025
Q1 		$522K Sell
56,150
-490
-0.9% -$6.34K ﹤0.01% 2020
2024
Q4 		$787K Buy
56,640
+26,560
+88% +$482K ﹤0.01% 1901
2024
Q3 		$707K Sell
30,080
-17,080
-36% -$359K ﹤0.01% 1908
2024
Q2 		$754K Sell
47,160
-930
-2% -$16K ﹤0.01% 1827
2024
Q1 		$789K Sell
48,090
-2,130
-4% -$34.9K ﹤0.01% 1842
2023
Q4 		$696K Buy
50,220
+17,490
+53% +$226K ﹤0.01% 1873
2023
Q3 		$451K Sell
32,730
-360
-1% -$5.34K ﹤0.01% 2018
2023
Q2 		$564K Sell
33,090
-670
-2% -$9.72K ﹤0.01% 1930
2023
Q1 		$543K Buy
+33,760
New +$402K ﹤0.01% 1971

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Victory Capital Management's TYRA Position: Q1 2026 in Review

Victory Capital Management reduced its Tyra Biosciences (TYRA) stake by 19% in Q1 2026, selling an estimated $115K and leaving 15,230 shares worth $583K. The position accounts for ﹤0.01% of the portfolio, ranked #1996.

Victory Capital Management first reported a position in TYRA in Q1 2023 and has held it in 13 quarters since. The position peaked at $789K in Q1 2024. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • Victory Capital Management held 15,230 shares of Tyra Biosciences worth $583K as of Q1 2026.
  • Victory Capital Management sold 3,560 Tyra Biosciences shares in Q1 2026, an estimated $115K.
  • Tyra Biosciences made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1996 holding.
  • Victory Capital Management first reported a position in Tyra Biosciences in Q1 2023 and has held it in 13 quarters since.
  • Victory Capital Management's Tyra Biosciences position peaked at $789K in Q1 2024.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.